• A Correction to this article was published on 30 April 2018

Abstract

Changes in DNA methylation in cancer have been heralded as promising targets for the development of powerful diagnostic, prognostic, and predictive biomarkers. Despite the existence of more than 14,000 scientific publications describing DNA methylation-based biomarkers and their clinical associations in cancer, only 14 of these biomarkers have been translated into a commercially available clinical test. Methodological and experimental obstacles are both major causes of this disparity, but the genomic location of a DNA methylation-based biomarker is an intrinsic and essential property that also has an important and often overlooked role. Here, we examine the importance of the location of DNA methylation for the development of cancer biomarkers, and take a detailed look at the genomic location and other relevant characteristics of the various biomarkers with commercially available tests. We also emphasize the value of publicly available databases for the development of DNA methylation-based biomarkers and the importance of accurate reporting of the full methodological details of research findings.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The Cancer Genome Atlas: https://cancergenome.nih.gov/ The International Cancer Genome Consortium: http://icgc.org/

References

  1. 1.

    Laird, P. W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253–266 (2003).

  2. 2.

    Carroll, P. R. et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J. Natl Compr. Canc. Netw. 14, 509–519 (2016).

  3. 3.

    Exact Sciences. Clinical guidelines and quality measures. Cologuard http://www.cologuardtest.com/hcp/about-cologuard/clinical-guidelines (2017).

  4. 4.

    US Preventive Services Task Force. et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 315, 2564–2575 (2016).

  5. 5.

    The American Cancer Society medical and editorial content team. Colorectal cancer screening tests. The American Cancer Society http://www.cancer.org/content/cancer/en/cancer/colon-rectal-cancer/detection-diagnosis-staging/screening-tests-used.html (2017).

  6. 6.

    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Older Adult Oncology. NCCN http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf (2017).

  7. 7.

    Epigenomics AG. China FDA names Epigenomics’ blood-based Septin9 colorectal cancer test a most innovative medical product for 2015. Epigenomics http://www.epigenomics.com/china-fda-names-epigenomics-blood-based-septin9-colorectal-cancer-test-innovative-medical-product-2015/ (2016).

  8. 8.

    Poste, G. Bring on the biomarkers. Nature 469, 156–157 (2011).

  9. 9.

    Kern, S. E. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 72, 6097–6101 (2012).

  10. 10.

    Munafò, M. R. et al. A manifesto for reproducible science. Nat. Hum. Behav. 1, 0021 (2017).

  11. 11.

    Ioannidis, J. P. A. & Bossuyt, P. M. M. Waste, leaks, and failures in the biomarker pipeline. Clin. Chem. 63, 963–972 (2017).

  12. 12.

    van Gool, A. J. et al. Bridging the translational innovation gap through good biomarker practice. Nat. Rev. Drug Discov. 16, 587–588 (2017).

  13. 13.

    van Vlodrop, I. J. et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin. Cancer Res. 17, 4225–4231 (2011).

  14. 14.

    Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M. & Issa, J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141–196 (1998).

  15. 15.

    Gonzalgo, M. L. et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res. 58, 1245–1252 (1998).

  16. 16.

    Homma, N. et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci. 97, 51–56 (2006).

  17. 17.

    Deng, G., Chen, A., Hong, J., Chae, H. S. & Kim, Y. S. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 59, 2029–2033 (1999).

  18. 18.

    Licchesi, J. D. et al. Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene 29, 5923–5934 (2010).

  19. 19.

    Yoshikawa, H. et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28, 29–35 (2001).

  20. 20.

    Jain, S. et al. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS ONE 7, e35789 (2012).

  21. 21.

    Jain, S. et al. Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis. Hepatol. Res. 45, 1110–1123 (2015).

  22. 22.

    van Vlodrop, I. J. et al. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am. J. Pathol. 176, 575–584 (2010).

  23. 23.

    Buffart, T. E. et al. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br. J. Cancer 99, 1802–1807 (2008).

  24. 24.

    Kim, M. S. et al. A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma. Clin. Cancer Res. 13, 6658–6665 (2007).

  25. 25.

    Claus, R. et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J. Clin. Oncol. 30, 2483–2491 (2012).

  26. 26.

    Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350–1354 (2000).

  27. 27.

    Hegi, M. E. et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10, 1871–1874 (2004).

  28. 28.

    Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).

  29. 29.

    Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707–715 (2012).

  30. 30.

    Malmstrom, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916–926 (2012).

  31. 31.

    Malley, D. S. et al. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol. 121, 651–661 (2011).

  32. 32.

    Everhard, S. et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 11, 348–356 (2009).

  33. 33.

    Bienkowski, M. et al. Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. Clin. Neuropathol. 34, 250–257 (2015).

  34. 34.

    Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484–492 (2012).

  35. 35.

    Kulis, M. et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 44, 1236–1242 (2012).

  36. 36.

    Kang, J. Y. et al. Identification of long-range epigenetic silencing on chromosome 15q25 and its clinical implication in gastric cancer. Am. J. Pathol. 185, 666–678 (2015).

  37. 37.

    Hu, C. Y. et al. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin. Cancer Res. 20, 4349–4360 (2014).

  38. 38.

    Klutstein, M., Nejman, D., Greenfield, R. & Cedar, H. DNA methylation in cancer and aging. Cancer Res. 76, 3446–3450 (2016).

  39. 39.

    Easwaran, H. et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 22, 837–849 (2012).

  40. 40.

    Kristensen, L. S., Raynor, M. P., Candiloro, I. & Dobrovic, A. Methylation profiling of normal individuals reveals mosaic promoter methylation of cancer-associated genes. Oncotarget 3, 450–461 (2012).

  41. 41.

    Lehmann-Werman, R. et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc. Natl Acad. Sci. USA 113, E1826–E1834 (2016).

  42. 42.

    Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).

  43. 43.

    Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).

  44. 44.

    Goldman, M., Craft, B., Zhu, J. & Haussler, D. The UCSC Xena system for cancer genomics data visualization and interpretation [abstract]. Cancer Res. 77 (Suppl.), 2584 (2017).

  45. 45.

    Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).

  46. 46.

    Koch, A., De Meyer, T., Jeschke, J. & Van Criekinge, W. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data. BMC Genomics 16, 636 (2015).

  47. 47.

    Ehrlich, M. & Lacey, M. DNA methylation and differentiation: silencing, upregulation and modulation of gene expression. Epigenomics 5, 553–568 (2013).

  48. 48.

    Zhang, Y. A. et al. SHOX2 is a potent independent biomarker to predict survival of WHO Grade II-III diffuse gliomas. EBioMedicine 13, 80–89 (2016).

  49. 49.

    Jeschke, J., Collignon, E. & Fuks, F. Portraits of TET-mediated DNA hydroxymethylation in cancer. Curr. Opin. Genet. Dev. 36, 16–26 (2016).

  50. 50.

    Stewart, S. K. et al. oxBS-450K: a method for analysing hydroxymethylation using 450K BeadChips. Methods 72, 9–15 (2015).

  51. 51.

    Moran, S. et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 17, 1386–1395 (2016).

  52. 52.

    Iqbal, S. A., Wallach, J. D., Khoury, M. J., Schully, S. D. & Ioannidis, J. P. Reproducible research practices and transparency across the biomedical literature. PLoS Biol. 14, e1002333 (2016).

  53. 53.

    Freedman, L. P., Venugopalan, G. & Wisman, R. Reproducibility2020: Progress and priorities. F1000Res 6, 604 (2017).

  54. 54.

    Brazma, A. et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29, 365–371 (2001).

  55. 55.

    den Dunnen, J. T. et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum. Mutat. 37, 564–569 (2016).

  56. 56.

    Monk, D. et al. Recommendations for a nomenclature system for reporting methylation aberrations in imprinted domains. Epigenetics https://doi.org/10.1080/15592294.2016.1264561 (2016).

  57. 57.

    Van Neste, L. et al. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol. 12, 16 (2012).

  58. 58.

    Jeronimo, C. et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747–1752 (2001).

  59. 59.

    Hoque, M. O. et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. 23, 6569–6575 (2005).

  60. 60.

    Altimari, A. et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am. J. Clin. Pathol. 129, 756–762 (2008).

  61. 61.

    Cairns, P. et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7, 2727–2730 (2001).

  62. 62.

    Crocitto, L. E. et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 64, 821–825 (2004).

  63. 63.

    Goessl, C., Muller, M., Heicappell, R., Krause, H. & Miller, K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann. NY Acad. Sci. 945, 51–58 (2001).

  64. 64.

    Goessl, C. et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58, 335–338 (2001).

  65. 65.

    Gonzalgo, M. L., Nakayama, M., Lee, S. M., De Marzo, A. M. & Nelson, W. G. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 63, 414–418 (2004).

  66. 66.

    Gonzalgo, M. L., Pavlovich, C. P., Lee, S. M. & Nelson, W. G. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 9, 2673–2677 (2003).

  67. 67.

    Jeronimo, C. et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60, 1131–1135 (2002).

  68. 68.

    Rogers, C. G. et al. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J. Urol. 176, 2280–2284 (2006).

  69. 69.

    Roupret, M. et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer 122, 952–960 (2008).

  70. 70.

    Sunami, E. et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin. Chem. 55, 559–567 (2009).

  71. 71.

    Bastian, P. J. et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J. Urol. 179, 529–534 (2008).

  72. 72.

    Bryzgunova, O. E., Morozkin, E. S., Yarmoschuk, S. V., Vlassov, V. V. & Laktionov, P. P. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann. NY Acad. Sci. 1137, 222–225 (2008).

  73. 73.

    Chuang, C. K. et al. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect Prev. 31, 59–63 (2007).

  74. 74.

    Ellinger, J. et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71, 161–167 (2008).

  75. 75.

    Payne, S. R. et al. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 69, 1257–1269 (2009).

  76. 76.

    Trock, B. J. et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int. 110, 56–62 (2012).

  77. 77.

    Melotte, V. et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl Cancer Inst. 101, 916–927 (2009).

  78. 78.

    Loh, K. et al. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes Cancer 47, 449–460 (2008).

  79. 79.

    Warren, J. D. et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9, 133 (2011).

  80. 80.

    Lofton-Day, C. et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54, 414–423 (2008).

  81. 81.

    Schmidt, B. et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 10, 600 (2010).

  82. 82.

    van Kessel, K. E., Van Neste, L., Lurkin, I., Zwarthoff, E. C. & Van Criekinge, W. Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J. Urol. 195, 601–607 (2016).

  83. 83.

    Lofton-Day, C. & Ebert, M. Methods and nucleic acids for the detection of colorectal cell proliferative disorders. ES2587068T3 (2016).

  84. 84.

    Mitchell, S. M. et al. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer 14, 54 (2014).

  85. 85.

    Devos, T. et al. Method for methylation analysis. EP2479289B1 (2007).

Download references

Acknowledgements

The work of the authors is supported financially by the Maag Lever Darm Stichting (MLDS, grant FP13-15), the Universiteitsfonds Limburg/SWOL, and an SU2C- DCS International Translational Cancer Research Dream Team Grant (Stand Up To Cancer (SU2C)-AACR- DT1415, MEDOCC). SU2C is a programme of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

Author information

Affiliations

  1. Department of Pathology, GROW — School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands

    • Alexander Koch
    • , Zheng Feng
    • , Muriel X. Draht
    • , Veerle Melotte
    • , Kim M. Smits
    • , Leander Van Neste
    •  & Manon van Engeland
  2. Division of Medical Oncology, Department of Internal Medicine, GROW — School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands

    • Sophie C. Joosten
    • , Tim C. de Ruijter
    • , Kim M. Smits
    •  & Jurgen Veeck
  3. Lung Cancer Program, University of Pittsburgh Cancer Institute, The Hillman Cancer Center, Pittsburgh, PA, USA

    • James G. Herman
  4. BioBix: Laboratory of Bioinformatics and Computational Genomics, Department of Mathematical Modelling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium

    • Wim Van Criekinge
  5. Department of Mathematical Modelling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium

    • Tim De Meyer

Authors

  1. Search for Alexander Koch in:

  2. Search for Sophie C. Joosten in:

  3. Search for Zheng Feng in:

  4. Search for Tim C. de Ruijter in:

  5. Search for Muriel X. Draht in:

  6. Search for Veerle Melotte in:

  7. Search for Kim M. Smits in:

  8. Search for Jurgen Veeck in:

  9. Search for James G. Herman in:

  10. Search for Leander Van Neste in:

  11. Search for Wim Van Criekinge in:

  12. Search for Tim De Meyer in:

  13. Search for Manon van Engeland in:

Contributions

A.K., S.C.J., and M.v.E. researched data for the article, all authors made a substantial contribution to discussion of content, A.K., S.C.J., and M.v.E. wrote the manuscript, and all authors reviewed and/or edited the manuscript before submission.

Competing interests

M.v.E. receives research funding from MDxHealth. W.V.C. is a consultant of MDxHealth. The other authors declare no competing interests.

Corresponding author

Correspondence to Manon van Engeland.

Supplementary information

About this article

Publication history

Published

Issue Date

DOI

https://doi.org/10.1038/s41571-018-0004-4

Further reading